

Genomics-based Personalised prevention:

FEAM Spring Conference, 20 May 2016 Dr Hilary Burton, PHG Foundation Director



Outline of talk

- New genomic technologies may help 'solve the problems' of healthcare
- Primary and secondary prevention
- Genomic approaches to prevention
 - Understanding and acting on risk
 - Spotting early disease
- Challenges
- Highlighting work of PHG Foundation









About us

The PHG Foundation is a pioneering independent think-tank with a special focus on **genomics** and other **emerging health technologies** that can provide more accurate and effective personalised medicine.

- Active since 1997
- Member of Cambridge University Health Partners and Cambridge Institute of Public Health
- Funded by philanthropy, grants, and fees for commissioned work
- Undertakes analysis, knowledge brokering, advocacy for policy makers





Three challenges to healthcare

- Demographic changes
- Greater patient expectation
- Scientific and technological advances

Three solutions

- Increasing emphasis on prevention
- Placing the individual at the centre (empowerment)
- Radical re-organisation with care moved from hospital to community



Disease prevention

- Primary and secondary prevention
 - Reducing risk
 - Finding and treating early disease

Genomic contribution to understanding of disease risk

And new biomarkers for detecting disease early





Primary prevention

Traditional epidemiology and public health studies determinants of disease...

Environmental exposures

- Housing
- Water
- Infectious disease
- Nutrition
- Chemical and physical agents

Social and behavioural factors

- Poverty
- Lifestyle





Tackling risk factors: Geoffrey Rose


Strategies aimed at populations

- Many people must take precautions in order to prevent disease in a few – some may actually be harmed
- A prevention measure that brings large benefits to the community offers little to each participating individual
- How can individuals be motivated to change

High risk strategy

Segregation of a minority with special problems from the rest who need no attention

- Requires an active approach to identifying those at high risk
- Risks medicalising (and stigmatising) the high risk minority



The public health approach involves a shift in the entire distribution to the left.

From: reference 64

FIGURE 2.THE NORMAL DISTRIBUTION OF BLOOD PRESSURE IN A HUMAN POPULATION



Personalised primary prevention

- Recognises different types and levels of disease risk
- Tailors prevention according to risk
 - More effective
 - More cost effective
 - Avoids over-diagnosis
- Requires
 - Effective tests
 - Effective interventions





Genes and disease

Genes, environment and their interaction

- Single gene disorders
- Multifactorial disease
- Genes and environmental exposures (e.g. smoking, environmental hazards, foods, medicines, infectious agents)



Personalised preventive interventions

- Newborn screening
- Single gene disorders in adult life
 - Breast cancer or cardiac arrhythmias
 - Familial hypercholesterolaemia

Relevant to individual and family members

In the UK 120,000 individuals with FH go undetected

Baby screening: Life-saving scheme expanded

By James Gallagher Health editor, BBC News website © 5 January 2015 | Health



Newborn babies across England will be screened for more debilitating canadic diseases from Merclay.

Cystic fibrasis and sickle cell disease are already picked up in the heel-prick blood tast. Four rarar conditions will now also be tested for.





New opportunities arising from WGS

Whole genome sequencing revealed Mr Hedley's kidney failure was caused by a particular genetic variant. His family is also being tested and their blood pressure can now be effectively controlled by drugs available on the NHS.

He said:

"I was keen to take part in the project as I felt it was important to try and find out as much as possible about my condition for my daughter and granddaughter. Now that my daughter, Terri, has been given a diagnosis it means that her condition can be monitored every year to see if there are any changes.



Prof. Patrick Chinnery (centre) with Leslie
Hedley and his daughter Terri Parker. Photo
courtesy of Newcastle University and
photographer Mike Urwin



Multifactorial conditions: example of diabetes

Lifestyle and genes in the development of diabetes

- Multifactorial
 - Obesity
 - Lack of exercise
- Genetic susceptibility
 - Type 1 (factors affecting autoimmunity to pancreatic beta cells)
 - Type 2 (over 60 loci over many genes)
- Monogenic forms
 - Neonatal diabetes (known defects in several genes)
 - MODY mutations in various genes


Obesity: www.phgfoundation.org/briefing_notes/184 **Diabetes**: www.phgfoundation.org/reports/13538/



ontribution to


Prevention in multifactorial conditions (e.g. CHD)

- Fine tuning risk estimates
- Does it change the 'intervention' or advice?
- Does it help people to change lifestyle?
- How can we improve this?



Statins: Millions more to get drugs in controversial plans

By James Gallagher Health-editor, BBC News website Gr 18-July 2014 | Health | P



Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, Attwood S, Hollands GJ





d to offer cholesterol-lowering statins to millions more ad controversial expansion in prescribing.

land, Wales and Northern ireland are now eligible for my are at low risk of a heart attack or stroke.

, NICE, says it will save lives



Gene environment interaction

• Food (*e.g.* PKU, coeliac disease, coronary artery disease)



- Environmental pollutants
- Medicine (e.g. CYP2D6 slow metaholisers)
- Infectious agents
- Vaccines

e.g. mutations in MHC genes confer susceptibility to Dengue shock syndrome



Challenges in personalised prevention

- Developing the evidence base
- Integrating with other technologies
- Patient empowerment
- Ethics, legal and regulatory considerations
- Competence of health professionals
- Finding complementarity with public health programmes





The evidence base

- Limits of conventional epidemiological studies and randomised trials as data that gives us information about individual risk and effect
- Complexity of modelling and long timescales
- Constantly evolving technologies





Genomics and other relevant technologies contribute to personalised prevention

Data generation: omics, imaging, sensors, mobile phone apps

Data integration: big data, cloud computing, mobile connectivity and social networking

Data analysis: algorithms, machine learning, learning support systems





Empowering individuals for personalised prevention

Empowerment means:

- Self-determining own health and healthcare
- Shared decision-making

Empowerment requires capacity building:

- e.g. education, counselling, coaching
- Potential for self-education facilitated by internet, patient organisations or community activism

Comments

- Understanding risk and genetics is complex
- Changing lifestyle is hard
- Health professionals are not well prepared
- Danger of worsening health inequalities



ELSI example: genomics, risk stratification and the law: cardiovascular disease


 Risk estimates based on family history, physiological measurements, biomarkers, lifestyleand genomic susceptibility variants

Regulatory complexities

- International movement of data
- Who can offer genetic tests
- Are the tools IVDs?

Website

EU funded EPIC-CVD project www.phgfoundation.org/reports



foundation

making science work for health

Getting genomic medicine right: The need for a competent workforce

In the UK

- 73,000 physicians in specialist practice
- 60,000 in general practice




'Few of these specialists will escape the impact of genomics in the next few years'

'Most specialties are unprepared'



Competent workforce

The RCP group on genomics medicine



www.phgfoundation.org/education

Personalisation and the public health perspective

 Finding complementarity between major public health programmes aimed at population determinants of health and personalised prevention

Cultural and educational shift for public health

practitioners





Conclusions

- Prevention an important aspect of the genomics personalisation agenda not widely discussed
- Relevant in inherited and multifactorial disease
- Issues in implementation include:
 - Evidence, integration with other technologies, empowerment, regulatory issues around data, healthcare development, integration with public health programmes, developing the evidence base

foundation making science work for health

www.phgfoundation.org

hilary.burton@phgfoundation.org

